
Sai Parenteral's IPO
- Issue price
- ₹392
- Listing price
- ₹400
- +2.04%
- Current price
- ₹496.85
- +26.75%
- Subscribed
- 1.08x
- Issue size
- ₹409 Cr
- Listed on
- 2 Apr 2026
IPO timeline
- Opens24 MarTue
- Closes27 MarFri
- Allotment30 MarMon
- Refunds1 AprWed
- Demat credit1 AprWed
- Listing2 AprThu
Issue details
- Price band
- ₹372 – ₹392 per share
- Issue size
- ₹409 Cr
- Fresh issue
- None
- Offer for sale
- ₹409 Cr
- Issue type
- OFS
- Face value
- ₹5 per share
- Lot size
- 38 shares
- Minimum investment
- ₹14,896
- Listing on
- BSE, NSE
- Exchange code
- SAIPARENT · 7655
Lot size and investment
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 38 | ₹14,896 |
| Retail (Max) | 13 | 494 | ₹1,93,648 |
| S-HNI (Min) | 14 | 532 | ₹2,08,544 |
| B-HNI (Min) | 68 | 2,584 | ₹10,12,928 |
Reservation
- QIB
- 52,14,143 shares (50.00% of the Offer)
- NII
- 15,64,244 shares (15.00% of the Offer)
- Retail
- 36,49,901 shares (35.00% of the Offer)
Allotment status
The allotment for this IPO is final. Check whether you received shares on the registrar's website using your PAN, application number or demat account (DP / Client ID).
Check allotment on Bigshare Services- 1Open the registrar's allotment page and select this IPO from the list.
- 2Enter your PAN, application number or DP / Client ID.
- 3Submit to see the number of shares allotted, if any.
- Basis of allotment
- 30 Mar 2026
- Refunds initiated
- 1 Apr 2026
- Shares credited to demat
- 1 Apr 2026
- Listing
- 2 Apr 2026
Grey market premium (GMP)
- Current GMP
- ₹0
- 0.00%
- Estimated listing price
- ₹392
- Issue price ₹392
- Highest
- ₹0
- 18 Mar
- Lowest
- ₹0
- 18 Mar
GMP by day (₹ per share)
Day-wise GMP table
| Date | GMP | Premium | Est. listing |
|---|---|---|---|
| 1 Apr 2026 | ₹0 | 0.00% | ₹392 |
| 31 Mar 2026 | ₹0 | — | ₹392 |
| 30 Mar 2026 | ₹0 | — | ₹392 |
| 29 Mar 2026 | ₹0 | — | ₹392 |
| 28 Mar 2026 | ₹0 | — | ₹392 |
| 25 Mar 2026 | ₹0 | — | ₹392 |
| 24 Mar 2026 | ₹0 | — | ₹392 |
| 23 Mar 2026 | ₹0 | — | ₹392 |
| 21 Mar 2026 | ₹0 | — | ₹392 |
| 20 Mar 2026 | ₹0 | — | ₹392 |
| 19 Mar 2026 | ₹0 | — | ₹392 |
| 18 Mar 2026 | ₹0 | — | ₹392 |
- Kostak rate
- ₹0
GMP is an unofficial indicator from an unregulated market. It is shown for information only and is not a prediction of the listing price or a recommendation to apply.
Subscription status
- QIB1.73x
- NII (HNI)2.45x
- Retail0.12x
| Category | Shares offered | Shares bid for | Subscribed |
|---|---|---|---|
| Qualified Institutional Buyers (QIB) | 21,12,900 | 36,55,317 | 1.73x |
| Non-Institutional Investors (NII) | 16,22,876 | 39,76,046 | 2.45x |
| bNII — bids above ₹10 Lakh | 10,81,918 | 38,51,628 | 3.56x |
| sNII — bids ₹2 Lakh to ₹10 Lakh | 5,40,958 | 1,29,830 | 0.24x |
| Retail Individual Investors (RII) | 37,86,710 | 4,54,405 | 0.12x |
| Total | 75,22,486 | 81,24,285 | 1.08x |
Financials
- P/E (pre-issue)
- 72.19
- P/E (post-issue)
- 72.19
- EPS (₹)
- 5.43
- RoCE
- 9.28
- RoNW
- 5.09
- PAT Margin
- 8.93
Pre-issue P/E uses the shares outstanding before the IPO; post-issue P/E includes the new shares. Calculated by Be IPO Ready at the issue price.
| Period ended | 30 Sep 2025 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Revenue | 89.43 | 163.74 | 155.18 |
| OPM % | |||
| EBITDA | 16.24 | 39.44 | 31.70 |
| Net Profit | 7.76 | 14.43 | 8.42 |
| Debt | 76.07 | 93.95 | 118.79 |
| Assets | 376.24 | 272.39 | 268.10 |
Peer comparison
| Company | Issue size | P/E | RoNW | PAT margin | Subscribed | Listing gain |
|---|---|---|---|---|---|---|
| Sai Parenteral's This IPO | ₹409 Cr | 72.19 | 5.09% | 8.93% | 1.08x | +2.04% |
| Standard Glass Lining Technology Mainboard · listed 13 Jan 2025 | ₹410.05 Cr | 38.5 | 20.74% | 10.92% | 185.48x | +25.71% |
| Sahajanand Medical Technologies Mainboard · listed 23 Oct 2026 | ₹475.48 Cr | 57.91 | 2.31% | 4.29% | 14.2x | +7.89% |
| Gandhar Oil Refinery (India) Mainboard · listed 30 Nov 2023 | ₹500.69 Cr | 7.62 | 32.28% | 5.20% | 65.63x | +76.33% |
| GPT Healthcare Mainboard · listed 29 Feb 2024 | ₹525.14 Cr | 32.49 | 23.77% | 10.64% | 8.52x | +15.59% |
| Innova Captab Mainboard · listed 29 Dec 2023 | ₹570 Cr | 36.42 | 24.58% | 7.34% | 56.33x | +0.92% |
| Senores Pharmaceuticals Mainboard · listed 30 Dec 2024 | ₹582.11 Cr | 28.21 | 23.60% | 15.25% | 96.96x | +53.45% |
Peers are other recent IPOs from the same industry, closest in issue size. Ratios are as disclosed at the time of each issue. This is not the listed-peer table from the offer document.
IPO objectives
How Sai Parenteral's plans to use the money raised, as stated in the offer document.
- Capacity expansion and upgradation of manufacturing facilities₹110.8 Cr
- Establishment of a new R&D Centre;₹18.02 Cr
- Repayment / prepayment of certain outstanding borrowings₹14.3 Cr
- Working capital requirements₹33 Cr
- Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia); and₹33 Cr
- General corporate purposes
About Sai Parenteral's
Sai Parenteral Limited is an Indian pharmaceutical company engaged in the manufacturing of a wide range of sterile formulations. The company was established with the objective of providing high-quality and affordable injectable medicines, catering to both domestic and international markets. Over the years, it has built a strong presence in the pharma industry by focusing on compliance, quality standards, and consistent product delivery. The company is promoted by experienced professionals with deep domain knowledge in pharmaceutical manufacturing and regulatory requirements, which has helped in establishing a reliable operational framework. The company’s product portfolio primarily includes injectable formulations such as antibiotics, analgesics, and other therapeutic drugs used in hospitals and healthcare institutions. It follows a business model that combines contract manufacturing and direct marketing, enabling it to serve both institutional buyers and third-party clients. Sai Parenteral emphasises quality control, modern manufacturing facilities, and adherence to regulatory standards, which supports its long-term growth. By maintaining strong relationships with clients and focusing on operational efficiency, the company aims to expand its footprint in the competitive pharmaceutical sector.
Promoters and shareholding
Anil Kumar Karusala, Karusala Aruna, Vijitha Gorrepati
- Promoter holding, pre-issue
- 61.23%
- Promoter holding, post-issue
- 51.16%
Anchor investors
| Investor | Shares allotted | Amount | % of anchor book |
|---|---|---|---|
| Kotak Life Sciences Fund I | 7,65,282 | ₹30 Cr | 24.46% |
| INDIA EMERGING GIANTS FUND LTD. | 2,96,849 | ₹11.64 Cr | 9.49% |
| MORGAN STANLEY ASIA (SINGAPORE) PTE. | 3,82,650 | ₹15 Cr | 12.23% |
| KOTAK MAHINDRA LIFE INSURANCE CO.LTD. | 7,65,320 | ₹30 Cr | 24.46% |
| QUANT MOMENTUM FUND | 9,18,384 | ₹36 Cr | 29.36% |
Registrar, lead managers and documents
Lead manager
Company contact
Sai Parenteral's Ltd. Address Plot No 39 5th floor, Lavanya Arcade Jayabheri Enclave Gachibowli, K.V.Rangareddy, Seri Lingampally Hyderabad, Telangana, 500032
+91 79979 91301
cs@saiparenterals.comSai Parenteral's IPO: common questions
1.When does the Sai Parenteral's IPO open and close?
The Sai Parenteral's IPO opens on 24 Mar 2026 and closes on 27 Mar 2026.
2.What is the price band of the Sai Parenteral's IPO?
The price band is ₹372 – ₹392 per share, with a lot size of 38 shares and a minimum investment of ₹14,896.
3.What is the size of the Sai Parenteral's IPO?
The issue size is ₹409 Cr (OFS).
4.What is the GMP of the Sai Parenteral's IPO?
The last reported grey market premium is ₹0 per share as of 01 Apr 2026, 05:35 PM IST. GMP is unofficial and changes frequently.
5.When is the Sai Parenteral's IPO allotment?
The basis of allotment is expected on 30 Mar 2026. Allotment status can be checked with the registrar, Bigshare Services Private Limited.
6.When will the Sai Parenteral's IPO list?
The shares listed on 2 Apr 2026 on BSE, NSE.
7.Who is the lead manager of the Sai Parenteral's IPO?
The book running lead manager is Arihant Capital Markets Ltd., and the registrar is Bigshare Services Private Limited.
8.What will the money raised in the Sai Parenteral's IPO be used for?
As stated in the offer document, the proceeds are for: Capacity expansion and upgradation of manufacturing facilities; Establishment of a new R&D Centre;; Repayment / prepayment of certain outstanding borrowings; Working capital requirements; Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia); and.
9.How can my company launch an IPO like Sai Parenteral's?
Start with an IPO readiness assessment: eligibility for the Main Board, audited financials, governance, conversion to a public limited company and an indicative valuation. Be IPO Ready advises promoters through each step, from readiness to listing day.
For business owners
Your company could be the next listing
Businesses like these raise growth capital on the public markets every week. Tell us about yours and our advisors will tell you, plainly, whether an IPO is within reach and what it would take.
- Eligibility check against NSE Emerge, BSE SME and Main Board norms
- Indicative valuation and issue size for your business
- A clear timeline from readiness to listing day
Check if your business can list
Fill in the eligibility form and get an assessment of where you stand. It takes about five minutes.
Prefer to talk? Call +91 92130 20393